Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease
- Conditions
- Atrial FibrillationChronic Kidney Disease
- Interventions
- Registration Number
- NCT01668901
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
In this study, the investigators examine whether aspirin or warfarin is useful for atrial fibrillation patients with chronic kidney disease.
- Detailed Description
randomised open labelled prospective study
We enroll patients with CHADS2 score 1 non-valvular AF with chronic kidney disease, and analyze all thromboembolic event or major bleeding event during follow-up period. Warfarin group take dose adjusted warfarin (target INR 2.0-3.0) and aspirin group take aspirin 100mg daly.
Thromboembolic events: Ischemic stroke or systemic arterial occlusion Major bleeding: gastrointestinal bleeding or intracranial bleeding (code 430, code 431, code 432 by ICD-9-CM codes)
-\> Only the first event of each case will be used for the analysis
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- CHADS2 score 1 nonvalvular atrial fibrillation patients with chronic kidney disease
- HAS-BLED ≥30
- History of syncope or seizure within 1 year
- History of major bleeding event within 6 months
- BP>180/100
- Abnormal prothrombin time
- Hypersensitivity of aspirin or warfarin
- Folstein mini mental state examination score <26
- Taking or had taken other anticoagulants
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description warfarin warfarin medication aspirin Aspirin medication
- Primary Outcome Measures
Name Time Method Thromboembolic event through study completion, an average of 1 year Ischemis stroke and systemic thromboembolism
- Secondary Outcome Measures
Name Time Method Major bleeding through study completion, an average of 1 year
Trial Locations
- Locations (1)
Seoul Nationap University Hospital
🇰🇷Seoul, Korea, Republic of